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Atopic dermatitis (AD) is a chronic inflammatory skin disease predominantly mediated by 
T helper cells. While numerous adaptive immune mechanisms in AD pathophysiology have 
been elucidated in detail, deciphering the impact of innate immunity in AD pathogenesis has 
made substantial progress in recent years and is currently a fast evolving field. As innate 
and adaptive immunity are intimately linked, cross-talks between these two branches of 
the immune system are critically influencing the resulting immune response and disease. 
Innate immune recognition of the cutaneous microbiota was identified to substantially con-
tribute to immune homeostasis and shaping of protective adaptive immunity in the absence 
of inflammation. Disturbances in the composition of the skin microbiome with reduced 
microbial diversity and overabundance of Staphylococcus spp. have been shown to be 
associated with AD inflammation. Distinct Staphylococcus aureus associated microbial 
associated molecular patterns (MAMPs) binding to TLR2 heterodimers could be identified 
to initiate long-lasting cutaneous inflammation driven by T helper cells and consecutively 
local immune suppression by induction of myeloid-derived suppressor cells further favoring 
secondary skin infections as often seen in AD patients. Moreover dissecting cellular and 
molecular mechanisms in cutaneous innate immune sensing in AD pathogenesis paved the 
way for exploiting regulatory and anti-inflammatory pathways to attenuate skin inflammation. 
Activation of the innate immune system by MAMPs of non-pathogenic bacteria on AD 
skin alleviated cutaneous inflammation. The induction of tolerogenic dendritic cells, inter-
leukin-10 expression and regulatory Tr1 cells were shown to mediate this beneficial effect. 
Thus, activation of innate immunity by MAMPs of non-pathogenic bacteria for induction of 
regulatory T cell phenotypes seems to be a promising strategy for treatment of inflammatory 
skin disorders such as AD. These new findings demonstrate how detailed analyses identify 
partly opposing consequences of microbe sensing by the innate immune system and how 
these mechanisms translate into AD pathogenesis as well as new therapeutic strategies.
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introduction
The skin is the body’s outer interface organ forming a multi-layered barrier between the environ-
ment and the individual. To maintain integrity of the host and protect from potentially detrimental 
influences by pathogens or toxic substances, effective defense mechanisms have evolved. In 
addition, the skin is colonized by a multitude of bacteria forming the cutaneous microbiome 
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that provides essential functions for skin homeostasis. Thus 
 anti-bacterial immune responses must be tightly controlled to 
allow pathogen defense but also to preserve the composition 
of the microbiota in the absence of inflammation. Innate and 
adaptive immunity interact and orchestrate different qualities 
of immune responses. A breakdown in the symbiotic relation-
ship between the cutaneous microbiota and its host has been 
identified and is associated with skin inflammation in atopic 
dermatitis (AD) (1). Deciphering mechanisms of the innate 
immune system which promote skin inflammation in AD 
patients and identifying counter regulatory pathways that limit 
inflammation by shaping T helper cell responses have not only 
broadened our understanding of disease pathology but also 
opened up new therapeutic perspectives.
Atopic Dermatitis Pathogenesis: in the 
Beginning, it is All About T Cells
Atopic dermatitis is a frequent inflammatory skin disease affecting 
up to 10–20% of the children and approximately 3% of adults in 
western countries (2). Innate (mast cells, eosinophils, basophils, 
different types of dendritic cells (DC), innate lymphocytes, and 
myeloid-derived suppressor cells) and adaptive immune cells (B 
cells and T cells) are believed to contribute to the complex immune 
network underlying cutaneous inflammation in AD. Few of the 
experimental setups and studies trying to disclose a role for these 
different cell types for AD allow defining one of these cell types 
as causal for cutaneous inflammation with the exception of CD4+ 
T helper cells which have been shown in several studies, clinical 
trials, and mechanistic analyses to drive AD (3–5). Consequently, 
a closer look at the state of the art in regard to T cells in AD is 
essential to create a modern concept of AD pathogenesis and to 
develop new therapeutic strategies.
In AD, a dense infiltrate of activated CD4+ T cells can be 
detected in the dermis especially in acute lesions (Figure 1) (6). To 
better understand the initiation of AD, analyses of atopy patch test 
lesions has contributed substantially. Analyses of cytokine expres-
sion revealed that T helper cells of early lesions produce IL-4, IL-5, 
and IL-13, hallmark cytokines of Th2 cells (7). Thus, the concept 
that was developed within the last 20  years was based on the 
interpretation that Th2 cytokines in the skin promote cutaneous 
inflammation in AD. As examples of Th2-associated pathology, the 
Th2-induced isotype switch in B cells leading to the production of 
IgE is frequently cited and IL-5 promoting maturation and survival 
of eosinophils are highlighted to play a role in some types of AD 
and other atopic diseases (8, 9). Mechanistic analyses have helped 
to understand how these Th2 cells are recruited to the skin also 
disclosing possible targets of new therapeutic strategies: cutaneous 
leukocyte antigen (CLA) as adhesion molecule allowing Th2 cells 
to roll on the luminal side of the high endothelial venules proved 
to be a good marker for T cells prone to migrate to the skin (10, 
11). CCR4 and CCR10 were shown to be prominent chemokine 
receptors allowing T cells to migrate through endothelia in the 
skin upon binding with the respective chemokines such as CCL17, 
CCL22, and CCL27 (11–13), and the chemokines binding CCR4 
are among the best biomarkers for AD inflammation (14). Once 
Th2 cells are recruited to AD skin, Th2 cell activation leads to 
the accumulation of high levels of Th2 cytokines. Interestingly, 
IL-4 orchestrates monocytes and DC to produce high amounts of 
CCR4-binding chemokines further amplifying Th2 cell recruit-
ment to the skin (15–17). Besides the effect on these immune cells, 
Th2 cytokines also fundamentally influence keratinocytes and how 
the epidermis responds to different stimuli. Th2 cytokines suppress 
the expression of terminal differentiation proteins of keratinocytes 
(filaggrin, loricrin and involucrin) therefore destabilizing cutane-
ous barrier function. In addition, Th2 cytokines have been shown 
to suppress the upregulation of antimicrobial peptides (AMP) in 
the skin upon stimulation such as beta defensin (HBD)-2, HBD-3, 
and LL-37 in keratinocytes. This failure to secrete AMPs to reach 
levels found in psoriasis has been argued to be the underlying 
mechanism of the susceptibility to bacterial and viral infections 
found in AD (18–20). Bacterial colonization on AD skin may 
be further supported by IL-4-mediated enhanced expression 
of fibronectin and fibrinogen acting as adhesion molecules for 
Staphylococcus aureus (21, 22). The Th1 cell and Th17 cell subsets 
are known for their potent anti-infectious properties controlling 
for intracellular and extracellular bacterial and fungal infections 
(23). Thus, demonstrating that IL-4 potently suppresses Th1 and 
Th17 cell immunity (24–28) further emphasized that AD skin is 
fundamentally more susceptible to cutaneous colonization and 
infection than normal or psoriasis skin. Most recent analyses even 
demonstrated that IL-4 reduces the Th17 inducing and maintain-
ing cytokine IL-23 in antigen presenting cells both in vitro and 
in vivo in humans (28). These findings highlight that analyzing the 
FiGURe 1 | Overview of T helper cell populations in acute and chronic 
dermatitis. In acute atopic dermatitis activated skin-resident DC migrate to 
local lymphnodes to prime naïve T helper cells and polarize them into a Th2 
phenotype. Th2 cells induce IgE class switching in B cells accounting for 
enhanced IgE levels regularly found in atopic dermatitis patients. Th2 cells are 
recruited back to the skin and induce cutaneous inflammation by effector 
cytokines accompanied by Th22 cells. In chronic atopic dermatitis, Th1 cells 
are increasingly part of the skin infiltrate consisting of Th1, Th2, and Th22 
cells.
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recruitment, persistence, and function of different Th cell subtypes 
into AD skin is of pivotal importance for better understanding AD 
and for disclosing the impact of bacteria for AD inflammation, its 
prevention, and resolution.
Th17 cells were characterized by the production of IL-17 
and IL-22 (29, 30). Following Th17 characterization, screening 
analyses were carried out for different diseases and tissues to 
better understand the Th17 cell function. Immunohistochemical 
studies revealed IL-17 production in acute AD lesions and 
confirmatory studies showed correlation of AD severity with 
the number of IL-17-producing T cells in peripheral blood 
and acute lesions (31, 32). Further characterization of IL-17-
producing T cells in acute AD lesions revealed that IL-17 was 
produced by newly described subsets of Th2/IL-17+ and Th0/
IL-17+ cells (33). Interestingly, IL-17 production by these subsets 
required stimulation by staphylococcal superantigens indicating 
interdependence of bacterial products and IL-17 in AD skin. 
It is still not understood why despite Th2 cytokines such as 
IL-4 suppressing IL-17 and IL-23, IL-17-producing cells are still 
detected in AD and whether IL-17 contributes to AD initiation 
or represents an epiphenomenon of cutaneous colonization and 
infection with bacteria in AD (27, 28, 33). Thus, the role of IL-17 
in AD needs further clarification and new drugs being avail-
able targeting IL-17 and IL-17R for the treatment of psoriasis 
such as secukinumab will soon shed light into the hitherto 
unknown role of IL-17 for AD. As microbiota also induce or 
condition for IL-17 production, defining the role of IL-17 for 
skin homeostasis, defense, and inflammation requires functional 
analyses, disclosure of the cellular network, and spatiotemporal 
differentiation.
More recently, another unique subset of T helper cells 
enriched in inflamed human skin producing IL-22 in the 
absence of IL-17 was identified and characterized (34). These 
Th22 cells express the skin homing chemokine receptors CCR4 
and CCR10 like Th2 cells and are distinct from Th17 cells as 
shown by transcriptome analyses (34, 35). Accumulation of 
Th22 cells was demonstrated in acute and chronic lesions of 
AD (36, 37) as were IL-22-producing CD8+ T cells (33, 36). 
IL-22 binds to a complex of IL-22R1 and IL-10R2 for induc-
tion of downstream signaling (38). IL-22R1 is not expressed on 
hematopoietic cells but rather can be detected on tissue-resident 
cells including keratinocytes (39). Functional consequences of 
IL-22 production are dependent on the target organ and the 
presence or absence of other cytokines, such as IL-17 or TNFα 
leading to either protective immune responses or inflammation 
(38, 40). IL-22 acting on keratinocytes has been reported to 
downregulate filaggrin expression and to affect expression of 
profilaggrin processing enzymes leading to further impairment 
of the epithelial barrier (41). Furthermore, IL-22 was reported 
to inhibit terminal differentiation of keratinocytes and to induce 
epidermal hyperplasia which is prominently seen in chronic AD 
(34). Thus IL-22-producing T cells may well play a crucial role 
in the pathogenesis of AD (42), however, the exact role cannot 
be defined based on the data available. Functions enhancing 
processes of both inflammation and regeneration describe Th22 
cells as a Janus-like player for AD.
Atopic Dermatitis Pathogenesis: Chronic 
and Self-Perpetuating inflammation 
Through Bacterial exposure
While acute flares of AD are characterized by an infiltrate consist-
ing of Th2 and Th22 cells, Th1 cells can be detected in chronic 
lesions of AD (Figure  1) in addition to Th2 and Th22 cells as 
early as 48 hours following elicitation of dermatitis (7, 37, 43). Th1 
cells are characterized by the transcription factor T-bet and the 
secretion of the inflammatory cytokine IFN-γ (44). In regard to the 
pathogenesis of chronic AD, IFN-γ was postulated to contribute 
to skin hypertrophy in chronic AD (45). IFN-γ strongly induces 
IL-22R1 on keratinocytes allowing IFN-γ and IL-22 to act together 
for induction of epidermal hyperplasia (39).
Th1 cells can be polarized from naïve T helper cells by DC secret-
ing large amounts of IL-12p70 (46, 47). As DC are at the interface 
of innate and adaptive immunity and build a dense network of 
immune sentinels in the skin, innate immune signals activating 
skin-resident DC were postulated to contribute to enhanced prim-
ing of Th1 cells in AD leading to chronic skin inflammation (48, 49). 
S. aureus colonization found in the majority of AD skin lesions and 
very early during lesion development has been shown to contribute 
to the release of pharmacological relevant amounts of Toll-like 
receptor (TLR2) agonists such as lipoteichoic acid (50). Binding of 
S. aureus-derived lipoteichoic acid to TLR2 on DC in vitro leads to 
DC maturation and production of the pro-inflammatory cytokines 
IL-12p70 and IL-23 resulting in enhanced Th1 and Th17 priming 
(51). Amplification of Th1 polarization is further achieved by 
the presence of the Th2 cytokine IL-4 acting on DC resulting in 
enhanced IL-12p70 production during T cell priming (52–54). As 
IL-4 is abundantly present in the skin of acute flares of AD as is S. 
aureus, combinatorial activation of DC by IL-4 and TLR2-ligands 
is a constant feature in AD skin. Based on this combined stimula-
tion of cutaneous DC, a profound shaping of consecutive immune 
response can be anticipated (55). Indeed, TLR2 activation together 
with IL-4R signaling transfers acute Th2-driven dermatitis (48 h 
before dermatitis resolution) into long-lasting skin inflammation 
(14 days) with enhanced expression of the Th1 cytokine IFN-γ 
(56). A key role could be ascribed to the Th2 cytokine IL-4 mediat-
ing suppression of the anti-inflammatory cytokine IL-10 while 
enhancing IL-12 (Figure 2). Administration of exogenous IL-10 
reverted chronic skin inflammation induced by TLR2 ligands and 
IL-4 indicating a crucial role for sustained production of IL-10 in 
response to cutaneous exposure to microbes. In conclusion, innate 
immune signals derived from S. aureus colonization or infection 
play a pivotal role in the transition of acute dermatitis into chronic 
skin inflammation and disease exacerbation highlighting a crucial 
role for microbes in the pathogenesis of AD (56). Furthermore, 
these mechanistic studies in AD models also revealed that IL-4 
is responsible for the transition of early self-limiting AD into 
chronic self-perpetuating AD as found in most of AD patients. 
These findings demonstrate that Th2 cytokines such as IL-4 and 
IL-13 are not only responsible for early AD lesions but also for the 
development and maintenance of chronic AD. This also explains 
why targeting AD by the recently described antibody dupilumab 
blocking both IL-4 and IL-13 is highly effective in AD patients. 
FiGURe 3 | S. aureus-derived lipoproteins induce MDSC. TLR2/6 
heterodimers are expressed on skin-resident cells. Binding of diacylated 
bacterial lipoproteins induces IL-6 secretion leading to accumulation and 
activation of MDSC in the skin. T cell activation is vigorously suppressed by a 
NO-dependent mechanism.
FiGURe 2 | Dual activation of skin-resident DC by iL-4 and TLR2 
ligands promotes iL-12 expression and Th1 polarization. In atopic 
dermatitis skin, Th2 cells secreting IL-4 are abundantly present. Skin-resident 
DC are activated by S. aureus derived TLR2 ligands (lipoproteins, lipoteichoic 
acid) in an IL-4 rich environment leading to DC maturation and enforced IL-12 
secretion by combinatorial activation of TLR2- and IL-4R-signaling while 
IL-10 production is markedly attenuated. As a consequence in the local 
lymph nodes, naïve T helper cells are preferentially polarized into a Th1 
phenotype promoting long-lasting cutaneous inflammation after homing to 
atopic dermatitis skin.
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Dupilumab is expected to be the first biologic being launched for 
AD treatment after having shown efficacy in several clinical trials 
(57). However, these analyses clearly highlight an intrinsic failure 
to terminate IL-4- and TLR2-driven chronic self-perpetuating AD 
as prominent feature of AD pathogenesis.
It can be anticipated that all types of inflammation, includ-
ing those of anti-infectious immune responses, induce immune 
pathways that are capable to terminate inflammation and to 
prevent exaggerated and self-perpetuating potentially harmful 
courses of inflammation. Recently, it could be shown that innate 
immune recognition of S. aureus induces, following TLR2-induced 
inflammation, immune suppression by induction of myeloid-
derived suppressor cells (MDSC) in a mouse model of AD (58). 
S. aureus-derived lipoproteins binding exclusively to the TLR2/6 
heterodimer on skin-resident cells trigger IL-6 secretion that leads 
to activation and recruitment of CD11b+ Gr1+ MDSC into the skin 
(Figure 3). These CD11b+ Gr1+ MDSC efficiently suppressed T cell 
recall responses in the skin by an iNOS-dependent pathway. These 
MDSC, however, fail to suppress AD inflammation, but rather 
inhibit anti-infectious immune responses allowing S. aureus to 
further spread and drive AD and possibly also herpes viruses to 
mount a dangerous AD complication, eczema herpeticum (58). 
These investigations show that innate immune recognition of 
pathogenic bacteria on the skin induces an anti-inflammatory 
pathway presumably to limit damage induced by inflammatory 
responses. Distinct temporal and spatial distributions may coor-
dinate these different and counter regulatory immune responses 
and understanding underlying mechanisms of attempts to prevent 
or resolve inflammation are important areas of research to identify 
new targets of treatments. Some of these mechanisms may be 
identified by the analyses that focus on the skin microbiome and 
immune consequences derived of the communication between the 
microbiome, the skin, and the cutaneous immune system.
Skin Microbiome
The skin is constantly colonized by myriads of bacteria with approxi-
mately 106 bacteria homing per square centimeter resulting in a 
total of 1010 bacteria covering the whole skin (59). The composition 
and distribution of the cutaneous microbiota have been deciphered 
in yet unknown details using deep sequencing techniques (60, 61). 
These techniques revealed a much more diverse microbiota as 
previously anticipated and detected using culture-based methods 
(61). The majority of bacteria identified by 16S ribosomal RNA 
sequencing can be assigned to four major phyla: Actinobacteria, 
Firmicutes, Bacteroidetes, and Proteobacteria (62). Importantly, 
16S rRNA sequencing also detected Gram-negative species at dry 
skin areas, which were previously seen as contaminants but not 
residents using culture-based techniques (63).
Examining different skin sites, it was found that the skin 
microbiota differs between topographical locations (60). The 
colonization of bacteria on the different areas of human skin is 
largely dependent on the physiology of the respective skin site. 
Whether the area is predominantly “moist,” “dry” or “sebaceous” 
impacts the respective microbiota to a large extent. At moist 
areas, Staphylococcus spp. and Corynebacterium spp. are the most 
abundant bacterial communities detected (59, 60). The highest 
diversity of phylotypes can be observed at dry skin areas like 
forearms, buttocks, and part of the hands with multiple species 
from the phyla Actinobacteria, Firmicutes, Bacteroidetes, and 
Proteobacteria being detected.
In contrast, sebaceous sites have the lowest diversity of phylo-
types with a predominance of Propionibacterium spp. confirming 
culture-based approaches showing that Propionibacterium spp. are 
commensals in areas rich in the “pilosebaceous units” consisting 
of hair, hair follicle, and sebaceous gland (60).
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Comparing interpersonal and intrapersonal variations of the 
skin microbiota at distinct topographical sites, it was shown that 
interpersonal variations are less than anticipated indicating that the 
colonized niche and its physiological features are a much stronger 
determinant for composition of the bacterial colonization than 
genetic variations of the individuals investigated (59, 62). In addi-
tion, the microbiota of one individual of, e.g., some sebaceous sites 
that share the same ecological features display a large similarity, 
further supporting the concept of cutaneous habitats determining 
the compositions of microbes by the cutaneous milieu.
Microbial colonization of the skin is established early in life. 
With birth, transition of the newborn’s surfaces derived from a 
sterile uterine milieu then exposed to a microbial-rich environment 
occurs. Thus, immediately after birth the skin of the newborn is 
being colonized (64). The mode of delivery has been shown to play 
a major impact on the composition of the skin microbiota of the 
newborn. Following vaginal delivery, the skin microbiota resembles 
the mother’s vaginal microbiota. In contrast, following cesarean 
delivery, the skin microbiota of the mother and the skin microbiota 
of the newborn show striking differences (64). The impact of these 
observations on the composition of the individual microbiota 
and the infant’s health is largely unknown, but consequences 
for immune responses have been postulated. Interestingly, the 
composition of the skin microbiota of 1 to 3-month-old children 
did not differ in regard to mode of delivery (65), whereas other 
studies demonstrated a striking stability of individual microbiota 
over time. Indeed, the microbiome of adults is maintained over 
time whereas the microbiome of children shows less stability 
and even an increase in microbial diversity over time (65). The 
consequences of individual microbiota developing at different time 
points for immune responses, immune tolerance development, and 
the “readiness” for defense are still a matter of debate. Whether 
disturbances and dysbiosis during the process of microbiota 
development influence susceptibility to skin diseases associated 
with dyscolonization of the skin remains to be established.
Functional Consequences of the Skin 
Microbiome
The studies of the intestinal and the cutaneous microbiome are for 
the most part descriptive in nature and associations of certain micro-
biota or of compositions within detected microbiota with diseases 
are increasingly being detected. However, functional consequences 
still need to be proven, underlying mechanisms of diseases need 
firm linkage to microbial exposure, and pathways of translating 
surface exposure to microbes into immune responses and memory 
still need to be established. Only few mechanisms of how the skin 
microbiome or specific microorganisms contribute to cutaneous 
immune homeostasis have been identified so far. Importantly, 
functional studies need to also involve pre-clinical analyses in 
disease models. However, animals with fur may not follow the same 
rules and algorithms as human skin in the absence of fur.
Much attention has been given to consequences of cutaneous 
exposure to staphylococci with the assumption of Staphylococcus 
epidermidis being the “good” part of the microbiome and S. aureus 
being the “bad” causing infections and disease. Indeed, cutaneous 
colonization of severe barrier-disrupted murine skin with S. aureus 
leads to expression of IL-1β, IL-6, and TNFα lasting for up to 
6 days demonstrating a pivotal role for S. aureus in promoting 
skin inflammation in susceptible hosts (66). After skin wounding 
and subsequently initiated inflammation due to TLR3-mediated 
detection of damaged cells, the skin commensal Staphylococcus 
epidermidis was identified to mediate resolution of cutaneous 
inflammation. Binding of Staphylococcus epidermidis derived 
lipoteichoic acid to TLR2 on keratinocytes was crucial in mediating 
this anti-inflammatory function via a TRAF1 dependent pathway 
(67). Recently, it was shown that recognition of S. epidermidis by 
the innate immune system profoundly shapes adaptive immune 
responses (68). Colonization of the skin with S. epidermidis 
activates antigen-specific T cells secreting IL-17 and IFN-γ in an 
IL-1R- and MyD88-dependent manner at steady-state conditions 
(68). Lack of commensals lead to a failure of induction of dermal 
IL-17- and IFN-γ-producing αβ T cells but raised the numbers 
of FoxP3+ regulatory T cells in the skin. To identify functional 
consequences of cutaneous S. epidermidis exposure, a model of 
Leishmania infection was applied showing that in the absence of 
sufficient immune sensing of S. epidermidis, Leishmania infection 
could not be controlled sufficiently (68). Further analysis of the 
cellular pathways involved in this process showed that IL-17-
producing T cells induced by S. epidermidis belong to the CD8+ 
subset displaying a unique and previously unknown role for these 
T cells in providing immune defense mechanisms in the skin (69). 
Thus, colonization of the skin with the commensal S. epidermidis 
provides innate immune signals to set up a functional threshold 
for adaptive immunity to establish pathogen control. Adaptive 
immune responses induced by the microbiota are required not 
only to fight pathogens but also to control colonization of the skin 
with commensals as in the absence of adaptive immunity com-
mensal bacteria were detected in the local lymph nodes indicating 
microbial invasion (70). Skin microbiota therefore seems to induce 
a feedback loop to control microbial colonization with commensals 
to maintain epithelial integrity and immune homeostasis.
Changes of the skin microbiota composition might therefore 
contribute to cutaneous inflammation seen in various skin diseases 
(71). Detailed analysis of the cutaneous microbiota of AD patients 
demonstrated dramatically reduced diversity of the microbiome 
analyzed from acute flares presenting at the antecubital and pop-
liteal crease (1). Instead of microbiota diversity overabundance of S. 
aureus and S. epidermidis was detected and correlated with disease 
severity confirming previous observations demonstrating S. aureus 
colonization and worsening of AD (1, 72). Of note, the “hen and 
egg problem” is not solved. Loss of microbiome diversity leading 
to skin flares or skin flares orchestrating dramatically reduced 
diversity of the microbiome are both possible scenarios. While 
for humans, the latter was thought to be the more likely cascade 
of events, new insights were brought forward by a mouse model.
A new model to study these changes from humans in detail 
including possibly causal relations was established most recently: 
mice lacking epidermal ADAM17 (Adam17ΔSox9, A17ΔKC) exhibit 
skin barrier disruption with enhanced transepidermal water loss 
(TEWL) and subsequently develop eczematous lesions with a lym-
phocytic infiltrate resembling human AD (73, 74). The skin micro-
biome of mice with disrupted barrier function due to epidermal 
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deficiency of ADAM17 (Adam17ΔSox9) was indistinguishable from 
wildtype littermates in the first 2 weeks after birth but showed 
decreased bacterial diversity and an abundance of Staphylococcus 
spp. and Corynebacterium spp. compared to wildtype controls 
starting 4 weeks after birth (74). Administration of antibiotics in 
Adam17ΔSox9 mice targeting S. aureus prevented the development 
of eczematous lesions and TEWL as well as cytokine production by 
CD4+ T cells and an increased number of skin-infiltrating T cells. 
Moreover, the microbiome showed a higher diversity – despite the 
use of antibiotics – and was comparable to the one of wildtype 
controls. In crossover experiments, antibiotic depletion of S. aureus 
in Adam17ΔSox9 mice resulted in reduction of eczematous lesions, 
reduced TEWL, attenuation of skin-infiltrating T cells, and reversal 
of dysbiosis. By contrast, withdrawal of antibiotics in previously 
administered Adam17ΔSox9 mice resulted in development of 
eczema, enhanced TEWL, increased skin-infiltrating T cells, and 
severe dysbiosis with excessive S. aureus colonization (74). These 
data clearly demonstrate that a shift of the microbiome resulting in 
dysbiosis with reduced microbial diversity and overrepresentation 
of S. aureus strikingly contributes to development of cutaneous 
inflammation and acute atopic flares in both mice with disrupted 
barrier and susceptible humans (1, 74). Thus enhancing the 
diversity of the microbiome to support colonization with puta-
tive non-pathogenic beneficial bacteria and/or targeting S. aureus 
colonization may be a therapeutic strategy in treatment of AD.
Resolution and Prevention of Atopic Skin 
inflammation
While functional analysis of the skin microbiome is currently in its 
beginnings, much more details on the functional properties of the 
gut microbiota were gathered (75, 76). At steady-state conditions, 
IL-17A- and IFN-γ-producing T cells can be found in the gut-
associated lymphoid tissue (GALT) and are required for prevention 
of inflammation by intestinal pathogens (77). Induction of these T 
cell populations has been shown to be dependent on the presence 
of the gut microbiota because in germ-free mice their numbers 
are significantly reduced (77, 78). This situation closely resembles 
what was found in the skin, namely turning off the local immune 
response by commensals to avoid inflammation by pathogens (71, 
79). In contrast to the skin, FoxP3+ regulatory T cells (Tregs) are 
abundantly present in the GALT especially lining the lamina propria 
and Treg induction is dependent on the intestinal microbiota (79, 
80). Several distinct mechanisms for induction of these regulatory 
T cells by the microbiota have been elucidated. Polysaccharide A 
(PsA) from Gram-negative Bacteroides fragilis has been shown to 
bind to TLR2 and to exert immune modulatory capacities in murine 
models of intestinal inflammation (81). The regulatory effects of 
PsA are due to induction of FoxP3+ iTregs and IL-10 secretion. 
Furthermore PsA is critical for maintaining immune homeostasis in 
the gut epithelium (81). A mixture of non-pathogenic Clostridium 
spp lacking toxins and virulence factors was identified to induce 
FoxP3+ Tregs in a TGF-β dependent manner preventing experimen-
tally induced intestinal inflammation (82, 83). Whether analogous 
approaches performed in animal models for the gut are also feasible 
to attenuate skin inflammation was not yet investigated.
Recently, it was shown by investigating humans that the 
diversity of the environmental microbiota and the prevalence 
of atopic diseases are interrelated and in atopic individuals a 
significant reduced diversity of Gammaproteobacteria at their 
surroundings and on their skin could be found (84). Relative 
abundance of Gammaproteobacteria was correlated with IL-10 
secretion by PBMCs of human healthy individuals while this 
IL-10 secretion was lacking in atopic patients. Investigations 
on the level of genus revealed that the reduced frequency of 
Gram-negative Acinetobacter best correlated with diminished 
IL-10 production in atopic individuals (84). Moreover, it was 
shown that heat-inactivated Acinetobacter Iwoffi induces IL-10 
production in DC and primary human keratinocytes in vitro and 
when applied intradermally (85). This work extends investigations 
that showed that Acinetobacter Iwoffi exposure of pregnant mice 
avoids allergic asthma development in their off springs (86). These 
findings highlighting a possibly beneficial role for Gram-negative 
bacteria both for prevention of atopic diseases and for maintaining 
skin microbiota propose to investigate new therapeutic strategies 
extending the regulation of the skin microbiome beyond the focus 
on Gram-positive bacteria such as S. epidermidis. We performed 
the first proof-of-concept RCT in humans to investigate whether 
signals derived from non-pathogenic Gram-negative bacteria may 
mediate beneficial effects for the skin with mild AD. Therefore, we 
initiated a randomized double-blind placebo-controlled clinical 
trial on AD patients using a lysate from Gram-negative Vitreoscilla 
filiformis. Groups of patients with AD received either vehicle cream 
or this vehicle cream supplemented with a lysate of V. filiformis 
for 29 days. A first analysis following 15 days of treatment already 
detected a significant change in the group treated with the V. fili-
formis supplemented cream. Following 29 days of treatment with 
V. filiformis-derived substances, a significant reduction of disease 
activity in patients receiving topical therapy with a cream contain-
ing V. filiformis was observed, moreover, intergroup comparison 
revealed a significant difference between groups demonstrating 
clinical efficacy of immune signals derived from Gram-negative 
V. filiformis (87). Consecutive work focused on underlying mecha-
nisms mediating immune modulation induced by immune signals 
derived from Gram-negative V. filiformis. To be able to analyze 
this mechanism of action possibly inducing tolerogenic immune 
responses effective on the skin, a mouse model for AD was utilized. 
Topical application of a lysate of V. filiformis, the Gram-negative, 
non-pathogenic bacterium, was shown to suppress skin inflam-
mation in Th2-dominated hypersensitivity in the AD-prone NC/
Nga mice (88). To unravel the underlying mechanisms, a series of 
in vitro and in vivo experiments was performed. It could be shown 
that V. filiformis lysate predominantly induces IL-10-producing 
DC in a TLR2-and MyD88-dependent manner. Priming of naïve 
T cells with DC activated by V. filiformis lead to the induction of 
Tr1 cells, which are characterized by their cytokine profile with 
high IL-10 and low IFN-γ levels (88, 89). The induction of IL-10high 
IFN-γlow Tr1 cells by innate immune signals from V. filiformis was 
dependent on DC-derived IL-10 and TLR2-signaling in DC. 
V. filiformis induced Tr1 cells had the capacity to suppress effector 
T cell proliferation and function demonstrating their regulatory 
function (Figure 4). Enhanced IL-10 production, reduced IFN-γ 
levels and diminished T cell proliferation in skin draining lymph 
FiGURe 4 | Non-pathogenic bacterium V. filiformis-derived MAMPs 
induce tolerogenic DC and Tr1 cells. V. filiformis-derived MAMPs activate 
DC to produce IL-10 via a TLR2-dependent mechanism. DC-derived IL-10 is 
required to subsequently polarize naïve T helper cells into a Tr1 phenotype 
characterized by low IFN-γ and high IL-10 secretion. Vf-induced Tr1 cells 
efficiently block effector T cells (Teff) demonstrating regulatory function for 
attenuating skin inflammation.
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nodes of mice topically treated with V. filiformis lysate compared to 
controls was observed demonstrating in vivo functionality of this 
approach (88). These data demonstrate that cutaneous exposure to 
innate immune signals derived of non-pathogenic Gram-negative 
bacteria is sufficient to induce long-lasting immune tolerance by 
induction of IL-10, that limited cutaneous exposure is capable 
to induce also systemic immune modulation, and that indirect 
supplementation of IL-10 lacking in atopic individuals by innate 
immune signals from non-pathogenic Gram-negative bacteria may 
be a feasible therapeutic approach to stabilize both the cutaneous 
barrier and immune homeostasis.
Summary
T helper cells play a key role in eliciting and maintaining AD inflam-
mation. Therefore, modulating T cell-elicited immune responses is 
a promising therapeutic approach. Th1- and Th1/Th17-mediated 
skin inflammation leading to psoriasis or cutaneous delayed-
type hypersensitivity reactions could be treated successfully by 
immune deviation approaches targeting T helper cell polarization 
and inducing immune deviation (25, 26, 28). The contribution of 
various T helper cell subsets (Th2, Th1 Th22, maybe Th17) to AD 
pathophysiology precludes application of this successful principle 
as it could be detrimental and result in worsening of disease sever-
ity. Thus, induction of tolerogenic immune responses promises 
to be a feasible strategy. Innate immune recognition of specific 
components or bacteria derived from the gut microbiota has been 
shown to induce tolerance based on induction of tolerogenic DC, 
regulatory T cells, and anti-inflammatory cytokines. This approach 
could by successfully applied to dampen AD inflammation by acti-
vating DC with innate immune signals of non-pathogenic bacteria 
resulting in induction of tolerogenic DC, priming of regulatory Tr1 
cells, and attenuation of cutaneous inflammation. After identifica-
tion of diminished bacterial diversity in the skin microbiome of 
atopic individuals with consecutive loss of anti-inflammatory and 
tolerogenic IL-10, substitution of these tolerance promoting innate 
immune signals using microbes or microbial components is a new 
and promising therapeutic strategy.
References
 1. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al.  Temporal 
shifts in the skin microbiome associated with disease flares and treatment in 
children with atopic dermatitis. Genome Res (2012) 22:850–9. doi:10.1101/
gr.131029.111 
 2. Bieber T. Atopic dermatitis. N Engl J Med (2008) 358:1483–94. doi:10.1056/
NEJMra074081 
 3. Woodward AL, Spergel JM, Alenius H, Mizoguchi E, Bhan AK, Castigli E, et al. 
An obligate role for T-cell receptor alphabeta+ T cells but not T-cell receptor 
gammadelta+ T cells, B cells, or CD40/CD40L interactions in a mouse model 
of atopic dermatitis. J Allergy Clin Immunol (2001) 107:359–66. doi:10.1067/
mai.2001.112695 
 4. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with 
atopic eczema – a systematic review and meta-analysis. J Eur Acad Dermatol 
Venereol (2007) 21:606–19. doi:10.1111/j.1468-3083.2006.02023.x 
 5. Staumont-Salle D, Fleury S, Lazzari A, Molendi-Coste O, Hornez N, Lavogiez 
C, et al.  CX(3)CL1 (fractalkine) and its receptor CX(3)CR1 regulate atopic 
dermatitis by controlling effector T cell retention in inflamed skin. J Exp Med 
(2014) 211:1185–96. doi:10.1084/jem.20121350 
 6. Leung DY, Bieber T. Atopic dermatitis. Lancet (2003) 361:151–60. doi:10.1016/
S0140-6736(03)12193-9 
 7. Grewe M, Walther S, Gyufko K, Czech W, Schöpf E, Krutmann J. Analysis of the 
cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic 
dermatitis patients. J Invest Dermatol (1995) 105:407–10. doi:10.1111/1523-1747.
ep12321078 
 8. Phipps S, Flood-Page P, Menzies-Gow A, Ong YE, Kay AB. Intravenous 
anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in 
allergen-challenged human atopic skin. J Invest Dermatol (2004) 122:1406–12. 
doi:10.1111/j.0022-202X.2004.22619.x 
 9. Ortega HG, Liu MC, Pavord ID, Brusselle GG, Fitzgerald JM, Chetta A, et al. 
Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J 
Med (2014) 371:1198–207. doi:10.1056/NEJMoa1403290 
 10. Berg EL, Yoshino T, Rott LS, Robinson MK, Warnock RA, Kishimoto TK, et al. 
The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the 
vascular lectin endothelial cell-leukocyte adhesion molecule 1. J Exp Med (1991) 
174:1461–6. doi:10.1084/jem.174.6.1461 
 11. Biedermann T, Schwärzler C, Lametschwandtner G, Thoma G, Carballido-
Perrig N, Kund J, et al.  Targeting CLA/E-selectin interactions prevents CCR4-
mediated recruitment of human Th2 memory cells to human skin in vivo. 
Eur J  Immunol (2002) 32:3171–80. doi:10.1002/1521-4141(200211)32:11 
<3171:AID-IMMU3171>3.0.CO;2-4 
 12. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, et al.  The chemokine 
receptor CCR4 in vascular recognition by cutaneous but not intestinal memory 
T cells. Nature (1999) 400:776–80. doi:10.1038/23495 
 13. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, et al.  CCL27-CCR10 
interactions regulate T cell-mediated skin inflammation. Nat Med (2002) 8:157–65. 
doi:10.1038/nm0202-157 
 14. Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A. Serum 
thymus and activation-regulated chemokine, macrophage-derived chemokine 
and eotaxin as markers of severity of atopic dermatitis. Allergy (2005) 60:685–8. 
doi:10.1111/j.1398-9995.2005.00774.x 
 15. Andrew DP, Chang MS, Mcninch J, Wathen ST, Rihanek M, Tseng J, et al.  STCP-1 
(MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes 
and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. 
J Immunol (1998) 161:5027–38. 
July 2015 | Volume 6 | Article 3538
Biedermann et al. Bacteria in atopic dermatitis
Frontiers in Immunology | www.frontiersin.org
 16. Vulcano M, Albanesi C, Stoppacciaro A, Bagnati R, D’Amico G, Struyf S, 
et  al.  Dendritic cells as a major source of macrophage-derived chemo-
kine/CCL22 in  vitro and in  vivo. Eur J  Immunol (2001) 31:812–22. 
doi:10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L 
 17. Xiao T, Fujita H, Saeki H, Mitsui H, Sugaya M, Tada Y, et al.  Thymus and 
activation-regulated chemokine (TARC/CCL17) produced by mouse epidermal 
Langerhans cells is upregulated by TNF-alpha and IL-4 and downregulated by 
IFN-gamma. Cytokine (2003) 23:126–32. doi:10.1016/S1043-4666(03)00221-7 
 18. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. 
Endogenous antimicrobial peptides and skin infections in atopic dermatitis. 
N Engl J Med (2002) 347:1151–60. doi:10.1056/NEJMoa021481 
 19. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, et al.  Cytokine 
milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction 
of innate immune response genes. J Immunol (2003) 171:3262–9. doi:10.4049/
jimmunol.171.6.3262 
 20. Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, et al.  Cathelicidin 
deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol (2006) 
117:836–41. doi:10.1016/j.jaci.2005.12.1345 
 21. Cho SH, Strickland I, Boguniewicz M, Leung DY. Fibronectin and fibrinogen 
contribute to the enhanced binding of Staphylococcus aureus to atopic skin. 
J Allergy Clin Immunol (2001) 108:269–74. doi:10.1067/mai.2001.117455 
 22. Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. 
Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated 
inflammation in a murine model. J Invest Dermatol (2001) 116:658–63. 
doi:10.1046/j.0022-202x.2001.01331.x 
 23. O’Connor W Jr, Zenewicz LA, Flavell RA. The dual nature of T(H)17 cells: shifting 
the focus to function. Nat Immunol (2010) 11:471–6. doi:10.1038/ni.1882 
 24. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, et al.  Cytokine-
induced immune deviation as a therapy for inflammatory autoimmune disease. 
J Exp Med (1994) 180:1961–6. doi:10.1084/jem.180.5.1961 
 25. Biedermann T, Mailhammer R, Mai A, Sander C, Ogilvie A, Brombacher F, 
et al.  Reversal of established delayed type hypersensitivity reactions following 
therapy with IL-4 or antigen-specific Th2 cells. Eur J Immunol (2001) 31:1582–91. 
doi:10.1002/1521-4141(200105)31:5<1582:AID-IMMU1582>3.0.CO;2-M 
 26. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, Van Eden W, et al. 
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human 
autoimmune disease. Nat Med (2003) 9:40–6. doi:10.1038/nm804 
 27. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al.  A distinct lineage 
of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat 
Immunol (2005) 6:1133–41. doi:10.1038/ni1261 
 28. Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, et al. 
IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in 
antigen-presenting cells. Proc Natl Acad Sci U S A (2015) 112:2163–8. doi:10.1073/
pnas.1416922112 
 29. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. 
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from 
the T helper type 1 and 2 lineages. Nat Immunol (2005) 6:1123–32. doi:10.1038/
ni1254 
 30. Ghoreschi K, Laurence A, Yang XP, Hirahara K, O’Shea JJ. T helper 17 cell 
heterogeneity and pathogenicity in autoimmune disease. Trends Immunol (2011) 
32:395–401. doi:10.1016/j.it.2011.06.007 
 31. Toda M, Leung DYM, Molet S, Boguniewicz M, Taha R, Christodoulopoulos 
P, et al.  Polarized in vivo expression of IL-11 and IL-17 between acute and 
chronic skin lesions. J Allergy Clin Immunol (2003) 111:875–81. doi:10.1067/
mai.2003.1414 
 32. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic 
role of Th17 cells for atopic dermatitis. J Invest Dermatol (2008) 128:2625–30. 
doi:10.1038/jid.2008.111 
 33. Eyerich K, Pennino D, Scarponi C, Foerster S, Nasorri F, Behrendt H, et al.  IL-17 
in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate 
immune response. J Allergy Clin Immunol (2009) 123(59–66):e54. doi:10.1016/j.
jaci.2008.10.031 
 34. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al.  Th22 
cells represent a distinct human T cell subset involved in epidermal immunity 
and remodeling. J Clin Invest (2009) 119:3573–85. doi:10.1172/JCI40202 
 35. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of 
interleukin 22 but not interleukin 17 by a subset of human skin-homing memory 
T cells. Nat Immunol (2009) 10:857–63. doi:10.1038/ni.1767 
 36. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, et al. 
IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis 
despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol (2009) 
123(1244–1252):e1242. doi:10.1016/j.jaci.2009.03.041 
 37. Gittler JK, Shemer A, Suarez-Farinas M, Fuentes-Duculan J, Gulewicz KJ, Wang 
CQ, et al.  Progressive activation of T(H)2/T(H)22 cytokines and selective 
epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy 
Clin Immunol (2012) 130:1344–54. doi:10.1016/j.jaci.2012.07.012 
 38. Eyerich S, Eyerich K, Cavani A, Schmidt-Weber C. IL-17 and IL-22: siblings, not 
twins. Trends Immunol (2010) 31:354–61. doi:10.1016/j.it.2010.06.004 
 39. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases 
the innate immunity of tissues. Immunity (2004) 21:241–54. doi:10.1016/j.
immuni.2004.07.007 
 40. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, 
inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 
(2011) 12:383–90. doi:10.1038/ni.2025 
 41. Gutowska-Owsiak D, Schaupp AL, Salimi M, Taylor S, Ogg GS. Interleukin-22 
downregulates filaggrin expression and affects expression of profilaggrin processing 
enzymes. Br J Dermatol (2011) 165:492–8. doi:10.1111/j.1365-2133.2011.10400.x 
 42. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic 
dermatitis and psoriasis – part II: immune cell subsets and therapeutic concepts. 
J Allergy Clin Immunol (2011) 127:1420–32. doi:10.1016/j.jaci.2011.01.054 
 43. Biedermann T, Röcken M, Carballido JM. TH1 and TH2 lymphocyte development 
and regulation of TH cell-mediated immune responses of the skin. J Investig 
Dermatol Symp Proc (2004) 9:5–14. doi:10.1111/j.1087-0024.2004.00829.x 
 44. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu 
Rev Immunol (2010) 28:445–89. doi:10.1146/annurev-immunol-030409-101212 
 45. Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS. Roles of TH1 and 
TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest (1999) 
103:1103–11. doi:10.1172/JCI5669 
 46. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM. Development 
of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. 
Science (1993) 260:547–9. doi:10.1126/science.8097338 
 47. Walsh KP, Mills KH. Dendritic cells and other innate determinants of T helper 
cell polarisation. Trends Immunol (2013) 34:521–30. doi:10.1016/j.it.2013.07.006 
 48. Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 
(2006) 144:1–9. doi:10.1111/j.1365-2249.2005.02980.x 
 49. Biedermann T. Dissecting the role of infections in atopic dermatitis. Acta Derm 
Venereol (2006) 86:99–109. doi:10.2340/00015555-0047 
 50. Travers JB, Kozman A, Mousdicas N, Saha C, Landis M, Al-Hassani M, et al. 
Infected atopic dermatitis lesions contain pharmacologic amounts of lipote-
ichoic acid. J Allergy Clin Immunol (2010) 125(146–152):e141–2. doi:10.1016/j.
jaci.2009.09.052 
 51. Volz T, Nega M, Buschmann J, Kaesler S, Guenova E, Peschel A, et al.  Natural 
Staphylococcus aureus-derived peptidoglycan fragments activate NOD2 and act 
as potent costimulators of the innate immune system exclusively in the presence 
of TLR signals. FASEB J (2010) 24:4089–102. doi:10.1096/fj.09-151001 
 52. Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski 
AK, et al.  IL-4 instructs TH1 responses and resistance to Leishmania major in 
susceptible BALB/c mice. Nat Immunol (2001) 2:1054–60. doi:10.1038/ni725 
 53. Yao Y, Li W, Kaplan MH, Chang CH. Interleukin (IL)-4 inhibits IL-10 to promote 
IL-12 production by dendritic cells. J Exp Med (2005) 201:1899–903. doi:10.1084/
jem.20050324 
 54. Guenova E, Volz T, Sauer K, Kaesler S, Müller MR, Wölbing F, et al.  IL-4-mediated 
fine tuning of IL-12p70 production by human DC. Eur J  Immunol (2008) 
38:3138–49. doi:10.1002/eji.200838463 
 55. Volz T, Kaesler S, Biedermann T. Innate immune sensing 2.0 – from linear 
activation pathways to fine tuned and regulated innate immune networks. Exp 
Dermatol (2012) 21:61–9. doi:10.1111/j.1600-0625.2011.01393.x 
 56. Kaesler S, Volz T, Skabytska Y, Köberle M, Hein U, Chen KM, et al.  Toll-like 
receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated 
suppression of IL-10. J Allergy Clin Immunol (2014) 134:92–9. doi:10.1016/j.
jaci.2014.02.017 
 57. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. 
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N 
Engl J Med (2014) 371:130–9. doi:10.1056/NEJMoa1314768 
 58. Skabytska Y, Wölbing F, Günther C, Koberle M, Kaesler S, Chen KM, et al. 
Cutaneous innate immune sensing of toll-like receptor 2-6 ligands suppresses 
July 2015 | Volume 6 | Article 3539
Biedermann et al. Bacteria in atopic dermatitis
Frontiers in Immunology | www.frontiersin.org
T cell immunity by inducing myeloid-derived suppressor cells. Immunity (2014) 
41:762–75. doi:10.1016/j.immuni.2014.10.009 
 59. Grice EA, Kong HH, Renaud G, Young AC, Bouffard GG, Blakesley RW, et al.  A 
diversity profile of the human skin microbiota. Genome Res (2008) 18:1043–50. 
doi:10.1101/gr.075549.107 
 60. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al.  Topographical 
and temporal diversity of the human skin microbiome. Science (2009) 324:1190–2. 
doi:10.1126/science.1171700 
 61. Kong HH, Segre JA. Skin microbiome: looking back to move forward. J Invest 
Dermatol (2012) 132:933–9. doi:10.1038/jid.2011.417 
 62. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol (2011) 9:244–53. 
doi:10.1038/nrmicro2537 
 63. Roth RR, James WD. Microbial ecology of the skin. Annu Rev Microbiol (1988) 
42:441–64. doi:10.1146/annurev.mi.42.100188.002301 
 64. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, 
et al.  Delivery mode shapes the acquisition and structure of the initial microbiota 
across multiple body habitats in newborns. Proc Natl Acad Sci U S A (2010) 
107:11971–5. doi:10.1073/pnas.1002601107 
 65. Capone KA, Dowd SE, Stamatas GN, Nikolovski J. Diversity of the human skin 
microbiome early in life. J Invest Dermatol (2011) 131:2026–32. doi:10.1038/
jid.2011.168 
 66. Wanke I, Skabytska Y, Kraft B, Peschel A, Biedermann T, Schittek B. Staphylococcus 
aureus skin colonization is promoted by barrier disruption and leads to local 
inflammation. Exp Dermatol (2013) 22:153–5. doi:10.1111/exd.12083 
 67. Lai Y, Di Nardo A, Nakatsuji T, Leichtle A, Yang Y, Cogen AL, et al.  Commensal 
bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. 
Nat Med (2009) 15:1377–82. doi:10.1038/nm.2062 
 68. Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, et al. 
Compartmentalized control of skin immunity by resident commensals. Science 
(2012) 337:1115–9. doi:10.1126/science.1225152 
 69. Naik S, Bouladoux N, Linehan JL, Han SJ, Harrison OJ, Wilhelm C, et al. 
Commensal-dendritic-cell interaction specifies a unique protective skin immune 
signature. Nature (2015) 520:104–8. doi:10.1038/nature14052 
 70. Shen W, Li W, Hixon JA, Bouladoux N, Belkaid Y, Dzutzev A, et al.  Adaptive immu-
nity to murine skin commensals. Proc Natl Acad Sci U S A (2014) 111:E2977–86. 
doi:10.1073/pnas.1401820111 
 71. Belkaid Y, Segre JA. Dialogue between skin microbiota and immunity. Science 
(2014) 346:954–9. doi:10.1126/science.1260144 
 72. Breuer K, Kapp A, Werfel T. Staphylococcus aureus: colonizing features and 
influence of an antibacterial treatment in adults with atopic dermatitis. Br J 
Dermatol (2002) 147:55–61. doi:10.1046/j.1365-2133.2002.04872.x 
 73. Franzke CW, Cobzaru C, Triantafyllopoulou A, Loffek S, Horiuchi K, Threadgill 
DW, et al.  Epidermal ADAM17 maintains the skin barrier by regulating EGFR 
ligand-dependent terminal keratinocyte differentiation. J Exp Med (2012) 
209:1105–19. doi:10.1084/jem.20112258 
 74. Kobayashi T, Glatz M, Horiuchi K, Kawasaki H, Akiyama H, Kaplan DH, et al. 
Dysbiosis and Staphylococcus aureus colonization drives inflammation in atopic 
dermatitis. Immunity (2015) 42:756–66. doi:10.1016/j.immuni.2015.03.014 
 75. Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity 
and inflammatory disease. Nat Rev Immunol (2013) 13:321–35. doi:10.1038/
nri3430 
 76. Sommer F, Bäckhed F. The gut microbiota – masters of host development and 
physiology. Nat Rev Microbiol (2013) 11:227–38. doi:10.1038/nrmicro2974 
 77. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al.  Induction of 
intestinal Th17 cells by segmented filamentous bacteria. Cell (2009) 139:485–98. 
doi:10.1016/j.cell.2009.09.033 
 78. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the 
intestinal microbiota and immune system. Nature (2012) 489:231–41. doi:10.1038/
nature11551 
 79. Belkaid Y, Bouladoux N, Hand TW. Effector and memory T cell responses to com-
mensal bacteria. Trends Immunol (2013) 34:299–306. doi:10.1016/j.it.2013.03.003 
 80. Geuking MB, Cahenzli J, Lawson MA, Ng DC, Slack E, Hapfelmeier S, et al. 
Intestinal bacterial colonization induces mutualistic regulatory T cell responses. 
Immunity (2011) 34:794–806. doi:10.1016/j.immuni.2011.03.021 
 81. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses 
during health and disease. Nat Rev Immunol (2009) 9:313–23. doi:10.1038/nri2515 
 82. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al.  Induction 
of colonic regulatory T cells by indigenous Clostridium species. Science (2011) 
331:337–41. doi:10.1126/science.1198469 
 83. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, et al.  Treg 
induction by a rationally selected mixture of Clostridia strains from the human 
microbiota. Nature (2013) 500:232–6. doi:10.1038/nature12331 
 84. Hanski I, Von Hertzen L, Fyhrquist N, Koskinen K, Torppa K, Laatikainen T, et al. 
Environmental biodiversity, human microbiota, and allergy are interrelated. Proc 
Natl Acad Sci U S A (2012) 109:8334–9. doi:10.1073/pnas.1205624109 
 85. Fyhrquist N, Ruokolainen L, Suomalainen A, Lehtimaki S, Veckman V, Vendelin 
J, et al.  Acinetobacter species in the skin microbiota protect against allergic sensi-
tization and inflammation. J Allergy Clin Immunol (2014) 134(1301–1309):e1311. 
doi:10.1016/j.jaci.2014.07.059 
 86. Conrad ML, Ferstl R, Teich R, Brand S, Blumer N, Yildirim AO, et al.  Maternal 
TLR signaling is required for prenatal asthma protection by the nonpathogenic 
microbe Acinetobacter lwoffii F78. J Exp Med (2009) 206:2869–77. doi:10.1084/
jem.20090845 
 87. Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P, Martin R, et al.  Effects of 
nonpathogenic Gram-negative bacterium Vitreoscilla filiformis lysate on atopic 
dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical 
study. Br J Dermatol (2008) 159:1357–63. doi:10.1111/j.1365-2133.2008.08836.x 
 88. Volz T, Skabytska Y, Guenova E, Chen KM, Frick JS, Kirschning CJ, et al. 
Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce 
IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol (2014) 
134:96–104. doi:10.1038/jid.2013.291 
 89. Cottrez F, Hurst SD, Coffman RL, Groux H. T regulatory cells 1 inhibit a 
Th2-specific response in vivo. J Immunol (2000) 165:4848–53. doi:10.4049/
jimmunol.165.9.4848 
Conflict of Interest Statement: The authors declare that the research was conducted 
in the absence of any commercial or financial relationships that could be construed 
as a potential conflict of interest.
Copyright © 2015 Biedermann, Skabytska, Kaesler and Volz. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal is cited, 
in accordance with accepted academic practice. No use, distribution or reproduction is 
permitted which does not comply with these terms.
